Immucell Share Price Today
(NASDAQ: ICCC)

Name: Immucell Share Price Today (NASDAQ: ICCC) - Immucell Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Immucell share price is $5.11 & ₹444.41 as on 6 Mar 2025, 2.30 'hrs' IST

$5.11

▲

-0.09

(-1.73%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Immucell share price in Dollar and Rupees. Guide to invest in Immucell stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Immucell, along with analyst recommendations, forecasts, and comprehensive financials.

Immucell share price movements

Today's Low: $5.11
Today's High: $5.24
$5.11
0.0%
Downside
Day's Volatility :2.48%
Upside
2.48%
52 Weeks Low: $3.34
52 Weeks High: $5.82
$5.11
34.64%
Downside
52 Weeks Volatility :42.61%
Upside
12.2%

Immucell (ICCC) Returns

Period	Immucell Corp	Index (Russel 2000)
3 Months	16.33%	0.0%
6 Months	36.13%	0.0%
1 Year	-0.95%	0.0%
3 Years	-35.32%	-11.6%

Immucell (ICCC) Key Statistics

in dollars & INR

Previous Close	$5.2
Open	$5.24
Today's High	$5.24
Today's Low	$5.11
Market Capitalization	$32.1M
Today's Volume	$156.0
52 Week High	$5.82
52 Week Low	$3.34
Revenue TTM	$23.2M
EBITDA	$-633.7K
Earnings Per Share (EPS)	$-0.49
Profit Margin	-17.44%
Quarterly Earnings Growth YOY	-0.63%
Return On Equity TTM	-16.1%

How to invest in Immucell Stock (ICCC) from India?

It is very easy for Indian residents to invest directly in Immucell from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Immucell stock in both Indian Rupees (INR) and US Dollars (USD). Search for Immucell or ICCC on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Immucell or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Immucell shares which would translate to 0.170 fractional shares of Immucell as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Immucell, in just a few clicks!

Returns in Immucell (ICCC) for Indian investors in Rupees

The Immucell stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Immucell investment value today

Current value as on today

₹1,02,296

Returns

₹2,296

(+2.3%)

Returns from Immucell Stock

₹2,667 (-2.67%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Immucell (ICCC)

-50%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Immucell Stock from India on INDmoney has decreased by -50% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Immucell

Vanguard Group Inc
2.53%
Renaissance Technologies Corp
1.54%
Cresset Asset Management, LLC
1.48%
Bleichroeder LP
1.14%
Dimensional Fund Advisors, Inc.
0.74%
Geode Capital Management, LLC
0.72%

Analyst Recommendation on Immucell

Buy

85%Buy

14%Hold

0%Sell

Based on 7 Wall street analysts offering stock ratings for Immucell(by analysts ranked 0 to 5 stars)

Based on 7 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Immucell Stock (ICCC)

What analysts predicted

Upside of 173.97%

Target:

$14.00

Current:

$5.11

Insights on Immucell Stock (Ticker Symbol: ICCC)

Price Movement
In the last 3 months, ICCC stock has moved up by 16.3%
Increasing Revenue
Revenue is up for the last 2 quarters, 5.47M → 6.01B (in $), with an average increase of 99.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -437.86K → -701.69M (in $), with an average decrease of 22981.6% per quarter
ICCC vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 64.2%
ICCC vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 85.6%
Price to Sales
ForICCC every $1 of sales, investors are willing to pay $1.7, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

ICCC Immucell Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$11.0M	↑ 5.32%
Net Income	$-2.3M	↑ 1282.14%
Net Profit Margin	-21.14%	↓ 19.53%

	FY19	Y/Y Change
Revenue	$13.7M	↑ 24.91%
Net Income	$-1.3M	↓ 44.19%
Net Profit Margin	-9.44%	↑ 11.7%

	FY20	Y/Y Change
Revenue	$15.3M	↑ 11.8%
Net Income	$-1.0M	↓ 21.14%
Net Profit Margin	-6.66%	↑ 2.78%

	FY21	Y/Y Change
Revenue	$19.2M	↑ 25.43%
Net Income	$-78.0K	↓ 92.37%
Net Profit Margin	-0.41%	↑ 6.25%

	FY22	Y/Y Change
Revenue	$18.6M	↓ 3.51%
Net Income	$-2.5M	↑ 3097.44%
Net Profit Margin	-13.43%	↓ 13.02%

	FY23	Y/Y Change
Revenue	$17.5M	↓ 5.9%
Net Income	$-5.8M	↑ 131.54%
Net Profit Margin	-33.05%	↓ 19.62%

	Q2 FY23	Q/Q Change
Revenue	$3.5M	↑ 2.5%
Net Income	$-1.4M	↓ 40.4%
Net Profit Margin	-39.06%	↑ 28.11%

	Q3 FY23	Q/Q Change
Revenue	$5.4M	↑ 52.76%
Net Income	$-940.0K	↓ 31.87%
Net Profit Margin	-17.42%	↑ 21.64%

	Q4 FY23	Q/Q Change
Revenue	$5.1M	↓ 5.57%
Net Income	$-1.1M	↑ 21.28%
Net Profit Margin	-22.37%	↓ 4.95%

	Q1 FY24	Q/Q Change
Revenue	$7.3M	↑ 42.42%
Net Income	$-437.9K	↓ 61.59%
Net Profit Margin	-6.03%	↑ 16.34%

	Q2 FY24	Q/Q Change
Revenue	$5.5M	↓ 24.59%
Net Income	$-1.5M	↑ 249.79%
Net Profit Margin	-27.99%	↓ 21.96%

	Q3 FY24	Q/Q Change
Revenue	$6.0B	↑ 109742.75%
Net Income	$-701.7M	↑ 45713.4%
Net Profit Margin	-11.67%	↑ 16.32%

	FY18	Y/Y Change
Profit	$5.2M	↓ 0.52%

	FY19	Y/Y Change
Profit	$6.7M	↑ 29.77%

	FY20	Y/Y Change
Profit	$6.9M	↑ 1.82%

	FY21	Y/Y Change
Profit	$8.7M	↑ 26.13%

	FY22	Y/Y Change
Profit	$7.6M	↓ 11.63%

	FY23	Y/Y Change
Profit	$4.4M	↓ 42.52%

	Q2 FY23	Q/Q Change
Profit	$1.0M	↑ 247.07%

	Q3 FY23	Q/Q Change
Profit	$1.3M	↑ 21.36%

	Q4 FY23	Q/Q Change
Profit	$1.3M	↓ 0.7%

	Q1 FY24	Q/Q Change
Profit	$2.3M	↑ 82.46%

	Q2 FY24	Q/Q Change
Profit	$1.2M	↓ 46.39%

	Q3 FY24	Q/Q Change
Profit	$1.6B	↑ 128593.38%

	FY18	Y/Y Change
Operating Cash Flow	$-373.4K	↓ 131.76%
Investing Cash Flow	$-1.8M	↓ 85.38%
Financing Cash Flow	$889.6K	↓ 90.87%

	FY19	Y/Y Change
Operating Cash Flow	$233.5K	↓ 162.54%
Investing Cash Flow	$-3.4M	↑ 89.71%
Financing Cash Flow	$6.9M	↑ 680.35%

	FY20	Y/Y Change
Operating Cash Flow	$1.3M	↑ 463.39%
Investing Cash Flow	$-2.6M	↓ 24.49%
Financing Cash Flow	$1.9M	↓ 72.47%

	FY21	Y/Y Change
Operating Cash Flow	$954.2K	↓ 27.47%
Investing Cash Flow	$-1.6M	↓ 37.84%
Financing Cash Flow	$3.9M	↑ 102.97%

	FY22	Y/Y Change
Operating Cash Flow	$-1.5M	↓ 261.8%
Investing Cash Flow	$-4.0B	↑ 248076.77%
Financing Cash Flow	$1.1M	↓ 71.27%

	Q1 FY23	Q/Q Change
Operating Cash Flow	$-2.8M	↑ 112.82%
Investing Cash Flow	$-682.2K	↓ 99.98%
Financing Cash Flow	$748.6K	↓ 401.61%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-681.4K	↓ 75.33%
Investing Cash Flow	$-708.4K	↑ 3.85%
Financing Cash Flow	$-251.9K	↓ 133.65%

Immucell Technicals Summary

Sell

Neutral

Buy

Immucell is currently in a neutral trading position according to technical analysis indicators.

Immucell (ICCC) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Immucell Corp	3.59%	36.13%	-0.95%	-35.32%	15.56%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Immucell Corp	NA	NA	0.0	0.0	-0.16	-0.05	NA	3.23
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Immucell Corp	Buy	$32.1M	15.56%	NA	-17.44%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Immucell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Organization	Immucell
Employees	0
CEO	Mr. Michael F. Brigham
Industry	Health Technology

Management People of Immucell

Name	Title
Mr. Michael F. Brigham	President, CEO, Principal Financial Officer, Treasurer, Secretary & Director
Ms. Bobbi Jo Brockmann	VP of Sales & Marketing and Director
Ms. Elizabeth L. Williams	Vice President of Manufacturing Operations
Ms. Elizabeth S. Toothaker	Director of Finance & Administration and Controller
Mr. A. Gustavo Scaffa	Senior Director of Quality
John W. Zinckgraf	Director of Product Development

Important FAQs about investing in ICCC Stock from India :

What is Immucell share price today?

Immucell share price today stands at $5.11, Open: $5.24 ; Previous Close: $5.20 ; High: $5.24 ; Low: $5.11 ; 52 Week High: $5.82 ; 52 Week Low: $3.34.

The stock opens at $5.24, after a previous close of $5.20. The stock reached a daily high of $5.24 and a low of $5.11, with a 52-week high of $5.82 and a 52-week low of $3.34.

Can Indians buy Immucell shares?

Yes, Indians can invest in the Immucell (ICCC) from India.

With INDmoney, you can buy Immucell at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Immucell at zero transaction cost.

How can I buy Immucell shares from India?

It is very easy to buy Immucell from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Immucell (ICCC) be purchased?

Yes, you can buy fractional shares of Immucell with INDmoney app.

What are the documents required to start investing in Immucell stocks?

To start investing in Immucell, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.